Summary :
The Venus VivaTM will now make its American premiere, having already established itself as a pioneer in the worldwide medical aesthetics sector among cutting-edge plastic surgeons, dermatologists, and aesthetic clinics throughout Europe, Asia, and Canada. Chairman and CEO Domenic Serafino gave his thoughts on the Venus VivaTM debut in a recent press release
About Vivjoa
Oteseconazole Structure
- API – Oteseconazole
- Indication – To reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of reproductive potential
- CAS number –1340593-59-0
- Mechanism of Action14-alpha demethylase inhibitors
“Based on our global clinical experience and market acceptance, Venus Viva™ has already established itself as ‘best in class’ technology,” says Domenic Serafino, Chairman and CEO of Venus Concept. “This minimally invasive, micro ablative technology has been designed with patient comfort in mind. It incorporates scanning technology allowing for tremendous clinical versatility and minimal downtime, while providing a very high level of patient comfort and satisfaction.”
This exciting news comes on the heels of an already impressive 2015 for us at Venus Concept, with treatments now being performed in over 50 countries worldwide, and over 3 million treatments each year.
For more Information: Sign in Websites for Agrochemical & Pharmaceutical Databases:
Website : https://www.chemrobotics.com/ (Agrochemical Databases)
Website : https://chemroboticspharma.com/ (Pharmaceutical Databases)
